|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
IMMUNOBIOLOGY
From the Department of Internal Medicine, University of
Iowa Hospitals and Clinics and VA Medical Center, Iowa City, and
DAKO GmbH, Hamburg, Germany.
Chronic rejection of transplanted allografts is the major cause of
graft loss after clinical solid organ transplantation. Recent data link
the indirect presentation of allopeptides to chronic graft loss; thus,
identification of immunodominant epitopes on major
histocompatibility complex (MHC) antigens could significantly contribute to establishing novel ways for monitoring and managing chronic rejection. Here, we show that synthetic allo-MHC-derived peptides covering the polymorphic region 56 to120 of HLA-B7 modulate alloresponses. In particular, the 2 Structural studies show that T-cell receptor (TCR)
contacts bind peptide and large stretches of Synthetic allopeptides have been used in many different models to
modulate alloresponses and to study alloreactivity.9-11 In
other studies, class I- and class II-derived allopeptides were used
to induce tolerance.12-14 By studying a series of
rat-derived synthetic allo-MHC peptides, immunodominant regions of
allogeneic MHC molecules that modulate graft survival were
identified.13 These studies revealed that some regions of
MHC class I molecules are not immunogenic and do not modulate
alloresponses. Thus, immunodominant peptides are defined here as
peptides derived from an allo-MHC molecule and capable of inducing
alloresponses. In human studies, peptide sequences that were able to
block alloreactive human T cells were reported.15,16 Some
of these peptides were found to be immunosuppressive in allogeneic
murine combinations,17 though overall their efficacy in
vivo has remained unclear.18 Recent studies provide
evidence that indirect presentation of allopeptides after clinical
organ transplantation is a major mechanism contributing to chronic
rejection.19-21 In a large-animal model, Lee et
al22 recently reported that indirect presentation of allopeptides promotes the development of cardiac allograft
vasculopathy. Thus, better definition and identification of
immunodominant sequences on the MHC molecule could significantly
enhance the management of patients undergoing allograft vasculopathy.
Dimeric and tetrameric MHC antigens have been extensively used to study
antigen-specific T cells.23-26 It has been possible to
visualize antigen-specific T cells by flow cytometry and also to study
T-cell regulation using MHC multimers.27 Here, we
synthesized a series of overlapping HLA-B7-derived peptides and used
them to detect the immunodominant regions of this molecule in
allogeneic reactions. By directly coupling fluorescein isothiocyanate
(FITC) to the synthesized peptide, we could use an immunodominant
HLA-B7-derived peptide to visualize anti-HLA-B7 CTL by flow
cytometry. The binding of these peptides to CTL was found to be
temperature-dependent. It was stable and specific at 4°C but not at
37°C. These studies show the potency of allogeneic synthetic peptides
to extend our knowledge of alloreactive T-cell epitopes and to enable
the study of their role in graft rejection.
Synthesis and FITC conjugation of MHC-derived allopeptides
To couple FITC to the peptides, the method by Kropshofer et
al30 was modified. Peptides attached to the solid support
were dissolved in 50 mM borate puffer and were mixed with FITC in a 1:3
molar ratio. In this way, it was possible to couple the peptides and
FITC at a 1:1 ratio. The solution was gently shaken for 6 hours, washed
3 times with borate buffer, and cleaved. Peptide purity was verified by HPLC.
Generation and peptide inhibition of alloreactive CTL
lines
In addition, anti-HLA-B7 CTLs were raised using allopeptides to pulse autologous antigen-presenting cells (APCs). Peripheral blood lymphocytes (PBLs) were isolated by Ficoll-Hypaque density gradient centrifugation from 5 non-HLA-B7 blood donors. Phytohemagglutinin blasts were grown from the PBLs of each individual and, after 5 days, were pulsed for 1 hour at 37°C with 10 µg/mL peptide compound made by mixing 50 µg each of the HLA-B7-derived peptides shown in Table 1. After irradiation at 20 Gy, the blast cells were cocultivated with autologous PBLs at a 1:1 cell ratio. Cell cultures were supplemented with 30 U/mL recombinant IL-2 and were restimulated every 5 to 7 days. Cytotoxicity was tested in a standard chromium-release assay.32 To test the effect of various allopeptides on the cytotoxicity of alloreactive CTLs, CTL-target cell ratios of 10:1 were plated on 96-well round-bottomed microtiter plates, and serial dilutions of the peptides were added, respectively. Chromium Cr 51 release was measured after 4-hour incubation. Peptide pulsing and stimulation of peripheral blood lymphocytes PBLs (2 × 105) were seeded in 96-well round-bottomed microtiter plates (Life Technologies, Paisley, United Kingdom) in RPMI 1640 medium (Life Technologies) supplemented with 15% AB-serum, 125 µg/mL penicillin, 250 µg/mL streptomycin, and 2 mM glutamine. An equal number of irradiated HLA-B7 stimulator cells (PBL or tumor cell lines) was added, and the cell mixture was left untreated or was supplemented with varying concentrations of peptide P3, P8, P10, P11, or P12. After 4 days of cocultivation, the cells were pulsed with 3H-thymidine for 18 hours. Stimulator and responder combinations used are shown in Table 2.Kinetics of peptide binding to CTL Serially diluted FITC-labeled peptides 11 and 21 were incubated with anti-HLA-B7-specific CTLs at 4°C for 60 minutes. The cells were washed 3 times with cold phosphate-buffered saline, and cell fluorescence was measured using a FACScan (Becton Dickinson, Mountain View, CA). To test the binding kinetics of the peptides used, peptide-labeled cells were further cultivated at either 4°C or 37°C in culture medium, aliquots of the cells were removed, and cell fluorescence was measured at various times.
Allogeneic immunodominant allopeptides are recognized by indirect presentation Allopeptides used in these studies ranged between 9 and 16 residues in length. They were synthesized and analyzed after purification by HPLC. Purity of the peptides was greater than 98%. To test whether the peptides were immunogenic in vitro, PBLs from non-HLA-B7 blood donors were gradient-separated and pulsed with serial dilutions of peptide P3, P8, P10, P11, P12, or P20. Cells were irradiated with 20 Gy and mixed with nonirradiated autologous PBLs at a 1:1 cell ratio. PBLs pulsed with P10 (91-105) and P12 (106-120) presented these peptides to autologous T cells, inducing proliferation. A representative assay performed with PBLs from a blood donor whose HLA phenotype was HLA-A2,-B57,-Cw6/-, DR7/- is shown in Figure 2A. Proliferation of these 2 peptides was significantly higher than that of untreated cells (P < .0001). As a positive control, Epstein-Barr virus-transformed B cells (HLA-A3,-B7,-C-,-DR-,-) were used as stimulator cells without the addition of peptides. P3 is an HLA-A2-derived peptide (residues 65-79) used as an irrelevant control peptide. Four of 5 blood donors responded to P10 and P12 by T-cell proliferation. None of the other peptides induced T-cell proliferation. To confirm that the peptides were presented indirectly by APCs, PBLs were depleted of APCs as we recently described,28 pulsed with the peptides, and used to stimulate nondepleted autologous PBLs. APC-depleted PBLs failed to present the allopeptides, indicating a requirement for indirect peptide presentation (Figure 2B). Furthermore antibodies against CD4, HLA-DR, and HLA-DP but not against CD8 or HLA-A, HLA-B, or HLA-Cblocked
peptide-induced T-cell proliferation (data not shown).
To test whether allopeptides modulate mixed lymphocyte reactions, PBLs from a non-HLA-B7 donor (HLA-A2,-B51,60 Cw3,-DR8,12) were cocultivated with irradiated stimulator cells derived from tumor cell line REH (HLA-A23,32 B35,50 Cw4,-DR3,5) at a 1:1 cell ratio. In addition, 50 µg/mL each peptide was added. The control coculture that was incubated with no peptide showed [3H]-thymidine uptake values of 28.500 ± 5.450 cpm. Proliferative changes that occurred after peptides were added to the cultures were expressed as percentages. Results of this responder-stimulator combination are shown in Figure 2C. Cells incubated with either P10 or P12 showed augmented proliferation, suggesting enhanced antigen presentation. However, of the 7 stimulator-responder combinations tested with these peptides, 6 showed strong responses to P10 and only 3 showed strong responses to P12. The results show peptide-induced enhanced proliferation, allowing speculation about whether indirect presentation of donor-derived MHC molecules shed during rejection episodes33 exacerbate rejection by enhancing T-cell sensitization. Allopeptides abrogate target cell lysis by anti-HLA-B7 alloreactive T cells Cytotoxic T cells were generated in vitro according to standard procedures. These CTLs were cytotoxic to HLA-B7 target cells, but not to control cells (Figure 3A). As we reported previously, Epstein-Barr virus-transformed cells, tumor cells, and PHA-blast cells expressing B7 were lysed by a single CTL line or clone, indicating that the specificity of the CTLs was peptide-dependent31 but not peptide-specific. However, allo-MHC-restricted CTLs have been well described and characterized in the literature,34,35 indicating heterogeneity in the specificity of polyclonal alloreactive CTLs.36 We further attempted to raise long-term T-cell cultures using autologous PBLs pulsed with a mixture of the B7-derived peptides. Responder cells used were from non-B7 blood donors. Three CTL lines were raised after repetitive restimulation with peptide-pulsed autologous PBLs. These cell lines were found to be more than 85% CD4+ and showed low cytotoxicity to B7 target cells, as would be expected (Figure 3B). To test whether allopeptides interfered with CTL target cell lysis, CTLs were incubated with serially diluted peptides and 51Cr-labeled target cells. P8 (60-75), P10 (91-105), and P11 (62-80) blocked CTL cytotoxicity (Figure 3C). Interestingly, P12 (106-120), which was readily presented in the proliferation assays leading to T-cell proliferation, failed to modulate CTL cytotoxicity in repetitive inhibition assays. In contrast, P8 was not presented in the proliferation assay, but it successfully blocked T-cell lysis of target cells, suggesting that the peptides presumably interacted with different T-cell populations in the 2 assays. HLA-A2-derived control peptide P3 (65-79) did not interfere with T-cell cytotoxicity. Conversely, when anti-HLA-A2 CTL line UWA2 was tested, only the A2-derived peptides P3 (65-79) and P4 (75-89), but not the B7-derived peptides, blocked CTL cytotoxicity, again indicating allospecificity of the peptides rather than their binding to the MHC alleles of the CTLs.
Visualization of alloreactive CTLs using FITC-labeled allopeptides Peptides P11 and P21, covering residues 62 to 70 of HLA-B7 and HLA-A2, respectively, were FITC-labeled, purified, and analyzed. Unlabeled P11 had a retention time of 35.46 minutes, whereas the labeled peptide had a delayed retention time of 44.65 minutes as analyzed by HPLC. The difference in retention times allowed efficient purification of the labeled peptides by HPLC.To test whether alloreactive CTLs can be labeled by allopeptides, an
anti-HLA-B7 CTL line, HNB7.1, was incubated with various concentrations of the FITC-labeled B7 peptide P11 at 4°C. Optimal staining of the cells was achieved with 250 µg/mL peptide (Figure 4). Control peptide P21 failed to stain
the CTL at this concentration, indicating that P11 was specific for
anti-HLA-B7 CTL. However, at 37°C, P21 stained 23% of the CTLs; in
contrast, it stained less than 1% at 4°C. This showed a
temperature-dependent increase in unspecific binding.
To further test whether peptide binding to T cells was influenced by CTL phenotype rather than by TCR binding, 2 CTL lines from the same responder (UW) were raised against HLA-A2 and HLA-B7. Peptide binding was tested by flow cytometry. Only UWB7 was labeled by P11 but not by P21. Conversely, UWA2 was labeled by P21 but not by P11, clearly confirming that peptide interaction with CTL was specificity regulated and was not determined by the HLA antigens present on the CTL lines. However, peptide binding could not be blocked by anti-TCR antibodies. This can be explained by the small molecular size of the peptides, which appeared not to be affected by possible steric conformational changes that occur after antibody binding to the TCR. To test the efficiency and specificity of P11 to label different CTL
lines, 6 CTL lines were generated in vitro. All CTLs were cytotoxic to
HLA-B7 target cells, as tested in a 4-hour 51Cr release
assay. In addition, 3 anti-HLA-A2 CTL lines were used as control CTLs.
Staining of the CTLs with the FITC-labeled peptide varied among the
different CTL lines and ranged from 21.2% to 97%, as shown on Table
3. This indicates that binding of
alloreactive CTLs to allopeptides is variable, presumably determined by
apparent affinities of the particular CTL lines studied. In contrast,
the anti-HLA-A2 CTL lines were poorly stained by P11.
Several factors govern the binding of any ligand to its receptor,
including affinity and temperature, which regulate binding-off rates
and specificity. HNB7.1 CTLs were labeled with P11 as described above,
and the cells were further incubated at 4°C or at 37°C. Cells were
removed at various time points, and cell fluorescence was measured by
flow cytometry (Figure 5). At 4°C,
binding intensity of the peptide to the CTL remained stable up to at
least 12 hours. In these experiments, cell vitality was greater than
95% at each time point. In contrast, at 37°C, cell fluorescence had
declined by more than 45% after 2 hours and by 60% after 5 hours.
Thus, the off-rates at 37°C appeared to be much higher than they did at 4°C.
Alloreactivity may result from the large number of MHC-peptide complexes found in normal cells, estimated as greater than 2000,37 to which a responding allogeneic T-cell population is not tolerant. The additive frequency of T cells reactive with such complexes on the allogeneic cell may be high.38 The complexity of the molecular requirements of alloreactivity have been described in great depth.6,7,39 A high proportion of alloreactive T cells reacts with antigenic sequences on allogenic MHC rather than with the endogenous peptide.36,40 These T cells are peptide-dependent but not peptide-specific. However, a subpopulation of alloreactive T cells is peptide-dependent and peptide-specific.35,36,41 This specificity is often driven by the molecular differences between donor and responder cells. When the structural differences between stimulator and responder MHC antigens are significant, T cells are often peptide-dependent but not peptide- specific. However, when responder and donor MHCs are structurally identical or similar, the endogenous peptide often dominates as the antigenic structure against which alloreactive T cells develop.6 Clinical evidence of the existence of peptide-specific alloreactive T cells is best illustrated in graft-versus-host disease,8 in which T cells react to minor histocompatibility antigens presented by MHC antigens. Unlike studies using mutagenesis to define epitopes of alloreactive T cells on the MHC molecule,4 we show here that synthetic peptides are useful candidates for defining MHC allospecificity. Interestingly, despite the differences in approach, both methods identify similar regions as immunogenic. The polymorphic MHC region covering residues 56 to 120 was chosen on
the basis of our own previous data and those of
others.9,13,28 In these earlier experiments, it was
demonstrated that peptides derived from the Indirect presentation of MHC molecules during graft rejection is an important mechanism that occurs during acute rejection and particularly during chronic rejection.43,44 Recently, Lee et al22 demonstrated that indirect recognition of allopeptides promotes the development of cardiac allograft vasculopathy in an inbred miniature swine model. Pigs immunized with swine leukocyte class I allopeptides showed in vitro proliferative responses and in vivo delayed-type hypersensitivity responses to the allogeneic peptides. More important, donor MHC class I disparate hearts transplanted into peptide-immunized cyclosporine-treated pigs not only were rejected more quickly than in unimmunized cyclosporine-treated controls, they developed obstructive fibroproliferative coronary artery lesions much earlier than did controls. These results for the first time link indirect presentation of alloantigen to clinical vasculopathy in a large animal model. Thus, the elevated donor-derived soluble MHC measured during rejection episodes and inflammation in general33 may contribute to the sensitization of even more T cells, exacerbating chronic rejection. Of all the peptides used in this study, P10 (residues 91-105) was best presented by HLA-A2 responder APCs to autologous T cells. This is interesting because this peptide contains the anchor positions for HLA-A2, leucine (residue 95) and valine (residue 103). Sequence alignment of P10 to the hepatitis B T-cell epitope described by Bertoletti et al45 shows similarity of these 2 peptides to each other at 3 positions, including the anchor residues. The fact that this peptide was well presented to T cells and successfully blocked alloreactive T cells clearly confirms the relevance of this sequence as an immunogenic T-cell epitope. MHC tetramers have been extensively used to identify antigen-specific T
cells23 and, more recently, peptide-specific alloreactive T
cells.35 However, synthetic peptides have virtually never been used to visualize alloreactive T cells. We therefore developed a
novel method for labeling synthetic peptides with FITC. Our data show
that the peptide derived from residues 62 to 70 sufficiently visualized
anti-HLA-B7 CTLs in specific fashion but did not visualize irrelevant
anti-HLA-A2 CTLs. There was low background staining at 4°C. However,
the binding capacity of CTLs was highly variable among the anti-HLA-B7
CTLs studied (range, 13.5%-97%). This variance might be attributed to
several factors. First, we used polyclonal CTL lines in these
experiments, implying that the CTL population in these cultures may be
heterogenous and may display different specificities on the HLA-B7
molecule. A CTL line with a high proportion of peptide-specific CTLs
would stain less than T cells that predominantly recognize the
The ability of the peptide-stained T cells to maintain their fluorescence was temperature-dependent. As observed recently with MHC-immunoglobulin complexes,46 the specificity of peptide binding was significantly reduced at 37°C. At this temperature, half the cells lost their fluorescence after 2 hours, possibly because of internalization, whereas fluorescence remained stable for 12 hours at 4°C. The affinities and off-rates of allopeptides are, therefore, highly temperature-dependent. Altogether, the current data indicate that it is feasible to identify CTL epitopes using synthetic peptides and that immunodominant peptides can be applied to visualize alloreactive T cells. In addition, allopeptides have the potential to regulate T cells by blocking their cytotoxicity against target cells.
We thank Kyoung-Ae Yoo Ott for her tremendous technical support in generating CTL lines and performing flow cytometry during the final stages of manuscript completion.
Submitted July 9, 2001; accepted December 18, 2001.
Supported by a grant from the Deutsche Forschungsgemeinschaft ZA (131/7-2), Bonn, and a generous grant from the Volkswagen Stiftung (AZ:I/72 735), Hannover, Germany. This study was performed at the Institute of Immunology at the University of Kiel, Germany.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Nicholas Zavazava, Department of Internal Medicine, University of Iowa Hospitals and Clinics, C51-F, 200 Hawkins Dr, Iowa City, IA 52242; e-mail: nicholas-zavazava{at}uiowa.edu.
1. Garboczi DN, Ghosh P, Utz U, Fan QR, Biddison WE, Wiley DC. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature. 1996;384:134-141[CrossRef][Medline] [Order article via Infotrieve].
2.
Garcia K, Degano M, Stanfield R, et al.
An 3. Benoist C, Mathis D. Demystification of the alloresponse. Curr Biol. 1991;1:143-144. 4. Smith K, Lutz C. Alloreactive T cell recognition of MHC class I molecules. J Immunol. 1997;158:2805-2812[Abstract].
5.
Obst R, Netuschil N, Klopfer K, Stevanovic S, Rammensee HG.
The role of peptides in T cell alloreactivity is determined by self- major histocompatibility complex molecules.
J Exp Med.
2000;191:805-812 6. Lechler R, Lombardi G, Batchelor J, Reinsmoen N, Bach F. The molecular basis of alloreactivity. Immunol Today. 1990;11:83-88[CrossRef][Medline] [Order article via Infotrieve]. 7. Eckels D. Alloreactivity: allogeneic presentation of endogenous peptide or direct recognition of MHC polymorphism? a review. Tissue Antigens. 1990;35:49-55[Medline] [Order article via Infotrieve].
8.
den Haan J, Sherman N, Blokland, et al.
Identification of a graft versus host disease-associated human minor histocompatibility antigen.
Science.
1995;268:1476-1480
9.
Fangmann J, Dalchau R, Fabre J.
Rejection of skin allografts by indirect allorecognition of donor class I major histocompatibility complex peptides.
J Exp Med.
1992;175:1521-1529 10. Dalchau R, Fangmann J, Fabre J. Allorecognition of isolated, denatured chains of class I and class II major histocompatibility complex molecules: evidence for an important role for indirect allorecognition in transplantation. Eur J Immunol. 1992;22:669-677[Medline] [Order article via Infotrieve].
11.
Sayegh M, Khoury S, Hancock W, Weiner H.
Induction of immunity and oral tolerance with polymorphic class II major histocompatibility complex allopeptides in the rat.
Proc Natl Acad Sci U S A.
1992;89:7762-7766 12. Fändrich F, Zhu X, Schröder J, et al. Different in vivo tolerogenicity of MHC class I peptides. J Leukoc Biol. 1999;65:16-27[Abstract]. 13. Zavazava N, Fändrich F, Zhu X, Freese A, Behrens D, Yoo-Ott K. Oral feeding of an immunodominant MHC-donor-derived synthetic class I peptide prolongs graft survival of heterotopic cardiac allografts in a high-responder rat strain combination. J Leukoc Biol. 2000;67:793-800[Abstract]. 14. Oluwole S, Chowdhury N, Jin M, Hardy M. Induction of transplantation tolerance to rat cardiac allografts by intrathymic inoculation of allogeneic soluble peptides. Transplantation. 1994;56:1523-1527. 15. Clayberger C, Parham P, Rothbard J, Ludwig D, Schoolnik G, Krensky A. HLA-A2 peptides can regulate cytolysis by human allogeneic T lymphocytes. Nature. 1987;330:763-765[CrossRef][Medline] [Order article via Infotrieve]. 16. Parham P, Clayberger C, Torn S, Ludwig D, Schoolnik G, Krensky A. Inhibition of alloreactive cytotoxic T lympocytes by peptides from the a2 domain of HLA-A2. Nature. 1987;325:625-628[CrossRef][Medline] [Order article via Infotrieve]. 17. Buelow R, Veyron P, Clayberger C, Pouletty P, Touraine J. Prolongation of skin allograft survival in mice following adminstration of allotrap. Transplantation. 1995;59:455-460[Medline] [Order article via Infotrieve]. 18. Nisco S, Vriens P, Hoyt G, et al. Induction of allograft tolerance in rats by an HLA class-I-derived peptide and cyclosporine A. J Immunol. 1994;152:3786-3792[Abstract]. 19. Ciubotariu R, Liu Z, Colovai A, et al. Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts. J Clin Invest. 1998;101:398-405[Medline] [Order article via Infotrieve].
20.
Hornick P, Mason P, Baker R, et al.
Significant frequencies of T cells with indirect anti-donor specificity in heart graft recipients with chronic rejection.
Circulation
2000;101:2405-2410
21.
Hornick P, Mason P, Yacoub M, Rose M, Batchelor R, Lechler R.
Assessment of the contribution that direct allorecognition makes to the progression of chronic cardiac transplant rejection in humans.
Circulation.
1998;97:1257-1263
22.
Lee R, Yamada K, Houser S, et al.
Indirect recognition of allopeptides promotes the development of cardiac allograft vasculopathy.
Proc Natl Acad Sci U S A.
2001;98:3276-3281
23.
Altman J, Moss P, Goulder P, et al.
Phenotypic analysis of antigen-specific T lymphocytes.
Science.
1996;274:94-96 24. Bieganowska K, Höllsberg P, Buckle G, et al. Direct analysis of viral-specific CD8+ T cells with soluble HLA-A2/Tax11-19 tetramer complexes in patients with human T cell lymphotropic virus-associated myelopathy. J Immunol. 1999;62:1765-1771.
25.
Daniels M, Jameson S.
Critical role for CD8 in T cell receptor binding and activation by peptide/major histocompatibility complex multimers.
J Exp Med.
2000;191:335-345
26.
Skinner P, Daniels M, Schmidt C, Jameson S, Haase A.
Cutting edge: In situ tetramer staining of antigen-specific T cells in tissues .
J Immunol.
2000;165:613-617
27.
Hamad A, O'Herrin S, Lebowitz M, et al.
Potent T cell activation with dimeric peptide-major histocompatibility complex class II ligand: the role of CD4 coreceptor.
J Exp Med.
1998;188:1633-1640 28. Stegmann S, Müller A, Zavazava N. Synthetic HLA-A2 derived peptides are recognized and presented in renal graft patients. Hum Immunol. 2001;61:1363-1369. 29. Freese A, Zavazava N. Determination of HLA-B7 T-cell epitopes. Transplant Int. 1996;9 (suppl):352-355.
30.
Kropshofer H, Max H, Kalbacher H.
Evidence for cobinding of self- and allopeptides to human class II major histocompatibility antigen DR1 by energy transfer.
Proc Natl Acad Sci U S A.
1993;90:403-407 31. Zavazava N, Hausmann R, Mueller-Ruchholtz W. Inhibition of anti-HLAB7 alloreactive CTL by affinity purified soluble HLA. Transplantation. 1991;51:838-842[Medline] [Order article via Infotrieve]. 32. Zavazava N, Krönke M. Soluble HLA class I molecules induce apoptosis in alloreactive cytotoxic T lymphocytes. Nat Med. 1996;2:1005-1010[CrossRef][Medline] [Order article via Infotrieve]. 33. Zavazava N, Böttcher H, Mueller-Ruchholtz. Soluble MHC class I antigens (sHLA) and anti-HLA antibodies in heart and kidney allograft recipients. Tissue Antigens. 1993;42:20-26[Medline] [Order article via Infotrieve].
34.
Levy RB, Gilheany PE, Shearer GM.
Role of self and foreign antigenic determinants in allogeneic and self- restricted cytotoxic T cell recognition.
J Exp Med.
1980;152:405-418
35.
Moris A, Teichgräber V, Gauthier L, Bühring H, Rammensee H.
Cutting edge: characterization of MHC restricted and peptide-selective alloreactive T cells using HLA-tetramer selection.
J Immunol.
2001;166:4818-4821
36.
Rötzschke O, Falk K, Faath S, Rammensee H.
On the nature of peptides involved in T cell alloreactivity.
J Exp Med.
1991;174:1059-1071
37.
Hunt D, Michel H, Dickinson T, et al.
Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad.
Science.
1992;256:1817-1820 38. Matzinger P, Bevan M. Hypothesis: why do so many lymphocytes respond to major histocompatibility antigens? Cell Immunol. 1977;29:1-5[CrossRef][Medline] [Order article via Infotrieve]. 39. Sherman L, Chattopadhyay S. The molecular basis of allorecognition. Annu Rev Immunol. 2001;11:385-402[CrossRef][Medline] [Order article via Infotrieve].
40.
Elliott T, Eisen H.
Cytotoxic T lymphocytes recognize a reconstituted class I histocompatibility antigen (HLA-A2) as an allogeneic target molecule.
Proc Natl Acad Sci U S A.
1990;87:5213-5217 41. Heath W, Hurd M, Carbone F, Sherman L. Peptide-dependent recognition of H-2Kb by alloreactive cytotoxic T lympocytes. Nature. 1989;341:749-752[CrossRef][Medline] [Order article via Infotrieve]. 42. Fangmann J, Dalchau R, Fabte J. Rejection of skin allografts by indirect allorecognition of donor class I major histocompatibility complex peptides. J Exp Med. 1992;175:1521-1529.
43.
Benichou G, Takizawa P, Olson C, McMillan M, Sercarz E.
Donor major histocompatibility complex (MHC) peptides are presented by recipient MHC molecules during graft rejection.
J Exp Med.
1992;175:305-308
44.
Liu Z, Sun Y, Xi Y, et al.
Contribution of direct and indirect recognition pathways to T cell alloreactivity.
J Exp Med.
1993;177:1643-1650
45.
Bertoletti A, Chisari F, Penna A, et al.
Definition of a minimal optimal cytotoxic T-cell epitope within the hepatitis-B virus nucleocapsid protein.
J Virol
1993;67:2376-2380 46. Fahmy T, Bieler J, Edidin M, Schneck J. Increased TCR avidity after T cell activation: a mechanism for sensing low-density antigen. Immunity. 2001;14:135-143[Medline] [Order article via Infotrieve].
© 2002 by The American Society of Hematology.
| ||||||||||
 |
|
 |
|
  A. Fried, M. Berg, B. Sharma, S. Bonde, and N. Zavazava Recombinant dimeric MHC antigens protect cardiac allografts from rejection and visualize alloreactive T cells J. Leukoc. Biol., September 1, 2005; 78(3): 595 - 604. [Abstract] [Full Text] [PDF]
|
|
| ||||
-pleated sheet-derived synthetic peptides are
immunodominant T-cell epitopes regulating alloresponses
Top
Abstract
Introduction
-pleated sheet-derived peptides covering residues 91 to 105 and 96 to 120, respectively, but not sequences from the 
1 helix, were presented by autologous peripheral blood lymphocytes to induce T-cell proliferation. In addition, the 2 
